Departments

Perioperative interruption of dual antiplatelet therapy (November 2017)

Elias B. Hanna, MD and Eliana Hanna Deschamps, MD
Cleveland Clinic Journal of Medicine April 2018, 85 (4) 261; DOI: https://doi.org/10.3949/ccjm.85c.04001

TO THE EDITOR: We read with great interest the article by Munyon et al1 addressing recent developments in perioperative medicine. We would like to comment on the perioperative interruption of dual antiplatelet therapy, a common clinical problem.

Several registry analyses have shown that, with second-generation drug-eluting stents, interruption of 1 antiplatelet agent after the first month is safe.2,3 These registries included a substantial proportion of patients whose index stenting procedure was performed for acute coronary syndrome (up to 60%).2 On average, antiplatelet therapy interruption was brief (about 6 to 7 days).

Additional registry analyses have shown that surgery may be safely performed beyond the first month after drug-eluting stent placement.4,5 Specifically, a large Danish analysis of patients with a drug-eluting stent who underwent noncardiac surgery, matched to control patients without ischemic heart disease, showed that the risk of perioperative myocardial infarction and death was not increased beyond the first month after drug-eluting stent implantation. Specifically, the risk was not increased at the 1- to 2-month and 2- to 12-month postimplantation intervals. Acute coronary syndrome was the indication for stenting in 56% of the patients.

Therefore, while surgery is preferably delayed 6 months after drug-eluting stent implantation (class I recommendation in the European Society of Cardiology guidelines), surgery may be selectively performed 1 to 6 months after drug-eluting stent implantation with an acceptable risk. This is particularly so if the index stenting was performed in the setting of stable coronary arterial disease (class IIa recommendation if stenting was performed in the setting of stable coronary arterial disease without complex procedural features; class IIb recommendation if stenting was performed in the setting of acute coronary syndrome or complex procedural features).6 After drug-eluting stent implantation, the earliest cutpoint for considering surgery is 1 month rather than 3 months.

When surgery is performed within this 1- to 6-month interval, thienopyridine interruption should be kept brief and dual antiplatelet therapy reinitiated as soon as possible postoperatively. In fact, when thienopyridine therapy is interrupted 1 to 6 months after drug-eluting stent implantation, stent thrombosis typically occurs more than 6 or 7 days after interruption.7

REFERENCES

  1. ↵
    1. Munyon R,
    2. Cohn SL,
    3. Slawski B,
    4. Smetana GW,
    5. Pfeifer K
    . 2017 update in perioperative medicine: 6 questions answered. Cleve Clin J Med 2017; 84(11):863–872. doi:10.3949/ccjm.84a.17068.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Ferreira-Gonzáles,
    2. Marsal JR,
    3. Ribera A,
    4. et al
    . Dual anti-platelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J Am Coll Cardiol 2012; 60(15):1333–1339. doi:10.1016/j.jacc.2012.04.057.
    OpenUrlFREE Full Text
  3. ↵
    1. Naidu SS,
    2. Krucoff MW,
    3. Rutledge DR,
    4. et al
    . Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. JACC Cardiovasc Interv 2012; 5(5):626–635. doi:10.1016/j.jcin.2012.02.014.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Egholm G,
    2. Kristensen SD,
    3. Thim T,
    4. et al
    . Risk associated with surgery within 12 months after coronary drug-eluting stent implantation. J Am Coll Cardiol 2016; 68(24):2622–2632. doi:10.1016/j.jacc.2016.09.967.
    OpenUrlFREE Full Text
  5. ↵
    1. Singla S,
    2. Sachdeva R,
    3. Uretsky BF
    . The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention. J Am Coll Cardiol 2012; 60(20):2005–2016. doi:10.1016/j.jacc.2012.04.062.
    OpenUrlFREE Full Text
  6. ↵
    1. Valgimigli M,
    2. Bueno H,
    3. Byrne RA,
    4. et al
    . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39(3):213–260. doi:10.1093/eurheartj/ehx419.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Airoldi F,
    2. Colombo A,
    3. Morici N,
    4. et al
    . Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116(7):745–754. doi:10.1161/CIRCULA-TIONAHA.106.686048
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Subjects